Edition:
United States

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

19.02USD
2:23pm EDT
Change (% chg)

$-0.34 (-1.76%)
Prev Close
$19.36
Open
$19.69
Day's High
$19.69
Day's Low
$19.00
Volume
23,791
Avg. Vol
14,035
52-wk High
$26.49
52-wk Low
$14.24

Latest Key Developments (Source: Significant Developments)

Merus Announces Q2 Loss Per Share Eur 0.20
Friday, 10 Aug 2018 08:35am EDT 

Aug 10 (Reuters) - Merus NV ::MERUS ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2018 & MID-YEAR OPERATING RESULTS.Q2 LOSS PER SHARE EUR 0.20.Q2 REVENUE EUR 6.5 MILLION VERSUS EUR 6.2 MILLION.Q2 REVENUE VIEW EUR 4.6 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW EUR -0.62 -- THOMSON REUTERS I/B/E/S.MERUS - EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2020.MERUS - ENDED Q2 WITH CASH, CASH EQUIVALENTS AND INVESTMENTS OF EUR 224.1 MILLION VERSUS EUR 190.8 MILLION AT DEC 31, 2017.  Full Article

Merus Announces First Patient Dosed In Phase 1 Clinical Trial Of Mcla-158 In Patients With Solid Tumors
Thursday, 24 May 2018 07:00am EDT 

May 24 (Reuters) - Merus NV ::MERUS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF MCLA-158 IN PATIENTS WITH SOLID TUMORS.MERUS NV - MERUS PLANS TO OPEN ADDITIONAL SITES FOR MCLA-158 TRIAL IN UNITED STATES.MERUS NV - IND ACCEPTED IN APRIL BY U.S. FDA FOR MCLA-158.  Full Article

Merus Q4 Loss Per Share EUR 0.73
Thursday, 26 Apr 2018 07:00am EDT 

April 26 (Reuters) - Merus NV ::MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017.Q4 LOSS PER SHARE EUR 0.73.Q4 EARNINGS PER SHARE VIEW EUR -0.62 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE WAS EUR 3.8 MILLION VERSUS NEGATIVE EUR 0.4 MILLION.EXPECTS THAT ITS CURRENT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH END OF 2020.  Full Article

Merus And Vall d'Hebron Institute Of Oncology Announce Research Collaboration
Tuesday, 20 Mar 2018 07:00am EDT 

March 20 (Reuters) - Merus Nv ::MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER.  Full Article

Merus Says Ono Pharma Exercised Option For New Research And License Agreement
Wednesday, 14 Mar 2018 07:00am EDT 

March 14 (Reuters) - Merus Nv ::MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES.MERUS NV - ‍ONO HAS AGREED TO FUND RESEARCH ACTIVITIES AT MERUS THAT WILL GENERATE CANDIDATE BICLONICS FOR NEW PROGRAM​.MERUS NV - ‍MERUS GRANTED ONO WORLDWIDE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RESULTING PRODUCTS DEVELOPED THROUGH COLLABORATION​.  Full Article

Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Simcere Pharmaceutical Group ::MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES.MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING CO'S BICLONICS TECHNOLOGY PLATFORM.MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS.MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE.MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS.MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE.  Full Article

Merus Nv Q3 Loss Per Share Eur 0.81
Thursday, 30 Nov 2017 07:00am EST 

Merus Nv ::MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS.Q3 LOSS PER SHARE EUR 0.81.Q3 REVENUE EUR 3.5 MILLION VERSUS EUR 1.2 MILLION.Q3 REVENUE VIEW EUR 2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW EUR -0.58 -- THOMSON REUTERS I/B/E/S.- ‍EXPECTS CURRENT CASH AND CASH EQUIVALENTS BALANCE TO BE SUFFICIENT TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS WELL INTO 2019​.  Full Article

Merus announces Q2 loss per share EUR 1.12
Tuesday, 19 Sep 2017 04:05pm EDT 

Sept 19 (Reuters) - Merus NV :Merus announces second quarter 2017 financial results and highlights recent progress.Q2 loss per share EUR 1.12.Q2 revenue EUR 4.0 million versus EUR 1.1 million.Q2 revenue view eur 2.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view EUR -0.52 -- Thomson Reuters I/B/E/S.Merus NV - Expects that current cash and cash equivalents balance will be sufficient to fund research and development programs, operations well into 2019.  Full Article

Merus Q1 loss per share EUR 1.15
Tuesday, 11 Jul 2017 04:05pm EDT 

July 11 (Reuters) - Merus Nv ::Merus announces first quarter 2017 financial results and mid-year operating results.Q1 loss per share EUR 1.15.Q1 revenue EUR 2.3 million versus EUR 800,000.Q1 revenue view EUR 42.8 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view EUR 1.55 -- Thomson Reuters I/B/E/S.Merus nv says by end of 2017, Merus expects to file a CTA for a first-in-human clinical trial of mcla-158 in patients with colorectal cancer.  Full Article

Merus reports Q4 loss per share eur 1.91
Friday, 28 Apr 2017 04:48pm EDT 

April 28 (Reuters) - Merus Nv -:Merus announces fourth quarter and full year 2016 financial results and corporate developments.Q4 loss per share eur 1.91.Q4 revenue eur 1.1 million versus eur 400,000.Q4 earnings per share view eur -0.52 -- Thomson Reuters I/B/E/S.Q4 revenue view eur 701090.00 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Merus Files Prospectus Relates To Proposed Resale Or Other Disposition Of Co's Shares By Selling Shareholders

* MERUS NV FILES PROSPECTUS RELATES TO PROPOSED RESALE OR OTHER DISPOSITION OF UP TO 3.1 MILLION OF CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source http://bit.ly/2jXQqy0 Further company coverage: